Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Phone: 212-426-7040
JFDI
JFDI Aug. 19 at 1:06 PM
$ARKG had a chance at going 3wt. Guess not
0 · Reply
RotationReport
RotationReport Aug. 13 at 5:49 PM
$ARKG no sellers
0 · Reply
gm2111111
gm2111111 Aug. 12 at 4:41 PM
$ARKG give us 50 already
0 · Reply
Woodman7
Woodman7 Aug. 12 at 1:58 AM
$CLNN $IBB $XBI $ARKG Further info on Clene presentation today:
0 · Reply
Woodman7
Woodman7 Aug. 12 at 1:38 AM
$CLNN $IBB $XBI $ARKG This is the perfect example of an “asymmetrical risk/reward” situation. The FDA has been essentially coaching CLNN management on how to best position their submission for accelerated approval. EVERYONE wants a breakthrough win in the fight against ALS. This may be it. I don’t see much downside risk at this price point even with a possible dilution towards the end of the year. IMHO, they have managed their funding needs tightly to date and have tried their best to minimize dilution effect on existing shareholders. Check out this write up. (Note: 2024= 2026 in attached)
1 · Reply
Scubafrank
Scubafrank Aug. 11 at 8:02 PM
$ARKG SOS at previous high of $44.46
0 · Reply
Dr_Stoxx
Dr_Stoxx Aug. 10 at 11:11 PM
$ARKG -- long in the ETF Trend Letter
0 · Reply
CactusPicksEm
CactusPicksEm Aug. 10 at 6:29 PM
$ARKG Nifty fifty coming swiftly
0 · Reply
Stockwhisperr
Stockwhisperr Aug. 10 at 3:30 PM
$BFLY Buckle up a voilent move is coming and it will leave many speechless and others in disbelief. BFLY has a huge pipeline despite the negative narrative from short sellers which are few and far between. If you follow smart money you will see only a handful of institutions are short. - Home healthcare commercial contract begins in Q4. - Pending FDA approval for 4th Gen chip - Apollo is in development and will likely be released to market in 2028 which is what MidJourney needs for their whole body scanners. - Workstations will be released in 2028 for hospitals seeking enterprise solutions - New partnerships for Butterfly Embedded, Butterfly Garden, Compass AI. - New revenue stream from entering the Brazil market - Software revenues will continue to grow. - BFLY transforming from a medical device to a semiconductor company. These are just a few in the pipeline. What’s coming will be epic in 2027! Few Understand 🦋 $ARKG $HYPR $AAPL $AAOI
2 · Reply
howardlindzon
howardlindzon Aug. 10 at 3:21 PM
0 · Reply
JFDI
JFDI Aug. 19 at 1:06 PM
$ARKG had a chance at going 3wt. Guess not
0 · Reply
RotationReport
RotationReport Aug. 13 at 5:49 PM
$ARKG no sellers
0 · Reply
gm2111111
gm2111111 Aug. 12 at 4:41 PM
$ARKG give us 50 already
0 · Reply
Woodman7
Woodman7 Aug. 12 at 1:58 AM
$CLNN $IBB $XBI $ARKG Further info on Clene presentation today:
0 · Reply
Woodman7
Woodman7 Aug. 12 at 1:38 AM
$CLNN $IBB $XBI $ARKG This is the perfect example of an “asymmetrical risk/reward” situation. The FDA has been essentially coaching CLNN management on how to best position their submission for accelerated approval. EVERYONE wants a breakthrough win in the fight against ALS. This may be it. I don’t see much downside risk at this price point even with a possible dilution towards the end of the year. IMHO, they have managed their funding needs tightly to date and have tried their best to minimize dilution effect on existing shareholders. Check out this write up. (Note: 2024= 2026 in attached)
1 · Reply
Scubafrank
Scubafrank Aug. 11 at 8:02 PM
$ARKG SOS at previous high of $44.46
0 · Reply
Dr_Stoxx
Dr_Stoxx Aug. 10 at 11:11 PM
$ARKG -- long in the ETF Trend Letter
0 · Reply
CactusPicksEm
CactusPicksEm Aug. 10 at 6:29 PM
$ARKG Nifty fifty coming swiftly
0 · Reply
Stockwhisperr
Stockwhisperr Aug. 10 at 3:30 PM
$BFLY Buckle up a voilent move is coming and it will leave many speechless and others in disbelief. BFLY has a huge pipeline despite the negative narrative from short sellers which are few and far between. If you follow smart money you will see only a handful of institutions are short. - Home healthcare commercial contract begins in Q4. - Pending FDA approval for 4th Gen chip - Apollo is in development and will likely be released to market in 2028 which is what MidJourney needs for their whole body scanners. - Workstations will be released in 2028 for hospitals seeking enterprise solutions - New partnerships for Butterfly Embedded, Butterfly Garden, Compass AI. - New revenue stream from entering the Brazil market - Software revenues will continue to grow. - BFLY transforming from a medical device to a semiconductor company. These are just a few in the pipeline. What’s coming will be epic in 2027! Few Understand 🦋 $ARKG $HYPR $AAPL $AAOI
2 · Reply
howardlindzon
howardlindzon Aug. 10 at 3:21 PM
0 · Reply
howardlindzon
howardlindzon Aug. 10 at 3:07 AM
this weeks momentum monday a bunch of new Ideas... $SPY $HACK $ARKG $QQQ
0 · Reply
ivanhoff
ivanhoff Aug. 10 at 3:02 AM
Momentum Monday - SPY at New All-Time Highs https://ivanhoff.com/2026/08/09/spy-at-new-all-time-highs-2/ @MarketSurge @howardlindzon $SPY $HACK $ARKG $QQQ
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Aug. 9 at 2:35 AM
$ARKG 👀
1 · Reply
howardlindzon
howardlindzon Aug. 8 at 7:06 PM
5 year highs in genomics sad but I am using $ARKG as my proxy any other etfs in this space ??
2 · Reply
CactusPicksEm
CactusPicksEm Aug. 7 at 9:47 PM
$ARKG so ripe
0 · Reply
raylin
raylin Aug. 7 at 7:44 PM
$ARKG Solid this year. Long ways from the $90S during COVID though.
0 · Reply
JFDI
JFDI Aug. 7 at 7:11 PM
More $ARKG in LT accounts. More thru 44.44 if we get it. Im gonna ask Cathy and @Doozio to be my dates to CES
0 · Reply
ETAlpha
ETAlpha Aug. 7 at 6:51 PM
$ARKG is trading strong around $42.72 right now! When those major call options flashed on the TMAD App a few days ago, my gut told me smart money was making a massive bet. Sure enough, the ETF has been ripping straight toward $44 ever since, and holding tight to this position feels incredible. With the breakout confirmed, hold core shares while managing risk near key supports, eyeing the $50 target ahead! Are you riding this biotech wave to new heights, or taking profits here?
0 · Reply
JFDI
JFDI Aug. 6 at 11:20 PM
0 · Reply
howardlindzon
howardlindzon Aug. 6 at 4:49 PM
just because $SPCX has stopoed going down does not mean it will rocket up i think max pain is just it goex nowhere everyone should have LONG updated watchlists to financials, healthcare, select tech and small caps and even biotechs $XBI $ARKG $XLF
3 · Reply
Stockwhisperr
Stockwhisperr Aug. 6 at 2:46 AM
$BFLY The second half of 2026 and first half of 2027 will bring revenue growth and expansion of multiple pipelines. The stock won’t be in the $7-8 for too long. We could see the stock at $11-12 by end of Q1 2027. - Revenue growth from Brazilian market - Final approval for FedRamp Certification will allow sales to VA and all federal government agencies. - Butterfly Home & Community Care entering commercial application. Once the program begins to generate cost savings for Optum there will be quick expansion into other states. Home healthcare takes $BFLY from $120 million revenues in 2026 to $180-200 million by end of 2027. - FDA approval for 4th Gen chip - Release of Apollo likely a year earlier than prior estimates. Apollo will be a game changer for BFLY and companies globally waiting for the chip. - iQ4 workstations for enterprise solutions to large institutions. - New partnerships for Butterfly Embedded, Compass AI, Butterfly Garden. Few Understand 🦋 $AAPL $PLTR $ARKG
1 · Reply
JFDI
JFDI Aug. 5 at 1:33 PM
0 · Reply